KEYLYNK-009
KEYLYNK-009: Phase II Trial of Maintenance Pembrolizumab + Olaparib vs Pembrolizumab + Chemotherapy in Untreated Metastatic or Locally Recurrent Inoperable TNBC

Released: December 07, 2023

Activity

Progress
1
Course Completed